Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice
René Etcheberrigaray(University of Illinois Chicago), Daniel L. Alkon(Blanchette Rockefeller Neurosciences Institute), Mathew Tan(University of Illinois Chicago), Cuno Kuipéri(KU Leuven), Ilse Dewachter(Hasselt University), Thomas J. Nelson(Blanchette Rockefeller Neurosciences Institute), Lixin Qiao(University of Illinois Chicago), Fred Van Leuven(KU Leuven), Barry Bank(University of Illinois Chicago), Alan P. Kozikowski(Chembio (United States)), Ingrid Van der Auwera(University of Illinois Chicago), Stefaan Wera(KU Leuven)
Cited by 339
Related Papers
Hallmarks of neurodegenerative diseases
|Cell|2023|1.6k
Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease
|JAMA Neurology|2019|876
Early Phenotypic Changes in Transgenic Mice That Overexpress Different Mutants of Amyloid Precursor Protein in Brain
|Journal of Biological Chemistry|1999|668
Serine/threonine protein phosphatases
|Biochemical Journal|1995|637
A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model
|Journal of Clinical Investigation|2004|622